Nurse Practitioner, Adult Health · Niagara Falls, NY
NPI
1588975288
Since 2010
Specialty
Nurse Practitioner, Adult Health
Code 363LA2200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
621 10th St
Niagara Falls, NY, 14301
Phone (716) 278-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
5,867 services
Medicare patients, 2024
194
Average age 72
Drug cost, 2024
$3.5M
4,665 prescriptions
Company payments, 2025
$3,205
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kathleen J Cloutier was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,280 times for 14 patients. In total Kathleen J Cloutier billed 5,867 services in 36 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,280 | 14 | $0.10 | $128 |
| 99213 Office E&M - Established | Office | 234 | 164 | $48.98 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 130 | 112 | $10.10 | $1,313 |
| 20610 Joint Injection | Office | 35 | 15 | $45.48 | $1,592 |
| 99214 Office E&M - Established | Office | 35 | 33 | $72.62 | $2,542 |
| 96372 Injection Administration | Office | 23 | 19 | $7.98 | $184 |
| 96365 Intravenous Infusion, Hydration | Office | 22 | 18 | $29.26 | $644 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 17 | 11 | $2.67 | $45.32 |
| 99204 Office E&M - New | Office | 12 | 12 | $68.27 | $819 |
By year: 2022 $104K for 8,427 services; 2023 $213K for 9,010 services; 2024 $75K for 5,867 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kathleen J Cloutier prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 951 prescriptions and refills. In total Kathleen J Cloutier wrote 4,665 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 951 | 1,471 | 223 | $23K |
| Prednisone Generic | 750 | 898 | 195 | $4,745 |
| Hydroxychloroquine Sulfate Generic | 486 | 832 | 122 | $19K |
| Allopurinol Generic | 225 | 358 | 45 | $2,692 |
| Sulfasalazine Dr Sulfasalazine | 203 | 284 | 49 | $7,383 |
| Sulfasalazine Generic | 183 | 292 | 49 | $5,679 |
| Gabapentin Generic | 149 | 208 | 30 | $1,917 |
| Folic Acid Generic | 133 | 314 | 37 | $908 |
| Alendronate Sodium Generic | 102 | 179 | 30 | $642 |
| Leflunomide Generic | 98 | 208 | 25 | $5,279 |
| Pregabalin Generic | 92 | 92 | 15 | $1,206 |
| Colchicine Generic | 87 | 96 | 23 | $6,964 |
| Actemra Tocilizumab | 69 | 69 | Under 11 | $283K |
| Duloxetine Hcl Generic | 65 | 122 | 16 | $1,477 |
| Methylprednisolone Generic | 61 | 62 | 40 | $529 |
Brand drugs: 999 claims; generic drugs: 3,666 claims; opioid claims: 67.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kathleen J Cloutier $3,205 ($3,205 in general payments such as food, travel and fees) from 16 companies. The largest payer was Amgen Inc. with $748.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 24 | $748 |
| UCB, Inc. UCB.BR | 20 | $669 |
| Abbvie Inc. ABBV | 25 | $644 |
| GlaxoSmithKline, LLC. GSK | 7 | $272 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $181 |
| Genentech USA, Inc. ROG.SW | 8 | $164 |
| Mallinckrodt Hospital Products Inc. | 3 | $102 |
| Pfizer Inc. PFE | 4 | $78.04 |
| Sandoz Inc. SDZ.SW | 3 | $68.73 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $61.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.